References
- Mahler DA, Wire P, Horstman D etal Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Grit. Care. Med 166, 1084–1091(2002).
- Calverley P, Pauwels R, Vestbo J etal for the TRISTAN ( TRial of Inhaled STemids ANd long-acting agonists)study group. Combined fluticasone and salmeterol in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 361, 449–456 (2003).
- GOLD: Global Strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease NHLBI/ WHO workshop report. Executive Summary, 1998.
- Anthonisen NR, Connett JE, Kiley JP etal Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAIVIA 272, 1497–1505 (1994).
- Report of the Medical Research Council Working Party: long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 318, 681–685 (1981).
- Boyd G, Morice AH, Pounsford JC eta]. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur. Rept:: J. 10, 815–821 (1997).
- Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am. J. Respir. Grit. Cam. Med 155, 1283–1289 (1997).
- Pauwels RA, Lofdahl CG, Laitinen LA etal Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl. J. Med 340, 1848–1853 (1999).
- The Lung Health Study Research Group. Effect of inhaled triamcinolone on decline in pulmonary function in chronic obstructive pulmonary disease. N Engl. J. Med 343, 1902–1909 (2000).
- Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised double-blind placebo-controlled study of fluticasone propionate in patients with moderate to severe COPD. Brit. Med 320, 1297–1303 (2000).
- Spencer S., Calverley PMA., Burge PS., Jones PW Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Grit. Care. Med 163, 122–128 (2001).
- Chapman KR. Seretide for obstructive lung disease. Expert Opin. Pharmacother 3, 341–350 (2002).
- Grove A, Lipworth BJ, Reid P etal Effects regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thomx5, 689–693 (1996).